Denali Therapeutics (NASDAQ:DNLI) Insider Sells $64,881.92 in Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Alexander Schuth sold 2,768 shares of Denali Therapeutics stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $23.44, for a total value of $64,881.92. Following the sale, the insider directly owned 278,995 shares of the company’s stock, valued at approximately $6,539,642.80. The trade was a 0.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Denali Therapeutics Stock Performance

Shares of DNLI stock opened at $22.28 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32. Denali Therapeutics Inc. has a fifty-two week low of $12.58 and a fifty-two week high of $27.30. The stock’s 50-day moving average is $24.44 and its two-hundred day moving average is $21.83. The firm has a market cap of $3.56 billion, a P/E ratio of -7.85 and a beta of 1.01.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The firm had revenue of $3.60 million during the quarter, compared to the consensus estimate of $2.15 million. During the same period in the previous year, the business earned ($0.72) earnings per share. Analysts predict that Denali Therapeutics Inc. will post -2.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Friday, July 17th. JPMorgan Chase & Co. started coverage on shares of Denali Therapeutics in a research note on Monday, July 13th. They set an “overweight” rating and a $29.00 price target on the stock. Robert W. Baird set a $34.00 price target on shares of Denali Therapeutics in a report on Friday, August 7th. Wall Street Zen cut shares of Denali Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Stifel Nicolaus set a $41.00 target price on shares of Denali Therapeutics in a research report on Monday, June 22nd. Fourteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Denali Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $35.85.

Institutional Investors Weigh In On Denali Therapeutics

A number of large investors have recently added to or reduced their stakes in DNLI. BlackRock Inc. bought a new position in shares of Denali Therapeutics in the second quarter valued at approximately $360,759,000. Vanguard Group Inc. boosted its holdings in shares of Denali Therapeutics by 8.9% during the 4th quarter. Vanguard Group Inc. now owns 13,057,890 shares of the company’s stock worth $215,586,000 after buying an additional 1,064,972 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in Denali Therapeutics by 28.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock valued at $119,766,000 after buying an additional 1,615,565 shares during the last quarter. Temasek Holdings Private Ltd raised its holdings in Denali Therapeutics by 30.9% in the 4th quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock worth $115,784,000 after acquiring an additional 1,657,142 shares during the period. Finally, State Street Corp lifted its position in Denali Therapeutics by 14.6% during the 4th quarter. State Street Corp now owns 6,263,371 shares of the company’s stock worth $103,408,000 after acquiring an additional 799,110 shares during the last quarter. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.